Breaking News

Capri EGM Acquires Lab and R&D Facility for Resilience

Resilience awarded DoD contract for mAb countermeasure to botulinum neurotoxins and has a multi-year agreement to produce mNRA for Moderna's Covid-19 vaccine.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Capri EGM, an investment company, has funded and acquired a newly constructed, state-of-the-art lab and R&D facility for National Resilience Inc (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption.    Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued at as much a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters